|Description||Drug development company|
|Seed, 7/2011 ||$2M|
|Venture Round, 11/2013 ||$15M|
Foresight Biotherapeutics is a clinical-stage drug development company pioneering novel therapies designed to address significant unmet needs in ophthalmology and otolaryngology.
Foresight’s platform Povidone-Iodine (PVP-I) technology represents an important breakthrough in the treatment of ocular and otic inflammation including bacterial, viral and fungal infections. This platform enables PVP-I, a well-characterized broad spectrum antiseptic with no known microbial resistance, to be formulated in combination with a range of anti-inflammatory agents.